BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32029494)

  • 1. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.
    Rotar Z; Svetina P; Tomsic M; Hočevar A; Prapotnik S
    BMJ Open; 2020 Feb; 10(2):e034356. PubMed ID: 32029494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
    Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area.
    Shimabuco AY; Medeiros-Ribeiro AC; Miossi R; Bonfiglioli KR; Moraes JCB; Gonçalves CR; Sampaio-Barros PD; Goldenstein-Schainberg C; Souza FHC; Prado LLD; Ugolini-Lopes MR; Yuki EFVN; Bonfa E; Saad CGS
    Clinics (Sao Paulo); 2020; 75():e1870. PubMed ID: 33146355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
    Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
    Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
    J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
    Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Iwaszko M; Wielińska J; Świerkot J; Kolossa K; Sokolik R; Bugaj B; Chaszczewska-Markowska M; Jeka S; Bogunia-Kubik K
    Front Immunol; 2021; 12():631603. PubMed ID: 34177886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
    Christensen IE; Lillegraven S; Mielnik P; Bakland G; Loli L; Sexton J; Uhlig T; Kvien TK; Provan SA
    Ann Rheum Dis; 2022 Mar; 81(3):398-401. PubMed ID: 34625404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study.
    Hellgren K; Ballegaard C; Delcoigne B; Cordtz R; Nordström D; Aaltonen K; Gudbjornsson B; Love TJ; Aarrestad Provan S; Sexton J; Zobbe K; Kristensen LE; Askling J; Dreyer L
    Rheumatology (Oxford); 2021 Aug; 60(8):3656-3668. PubMed ID: 33401297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
    Paul D; Patil D; McDonald L; Patel V; Lobo F
    J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
    [No Abstract]   [Full Text] [Related]  

  • 14. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
    Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
    Burmester GR; Cohen SB; Winthrop KL; Nash P; Irvine AD; Deodhar A; Mysler E; Tanaka Y; Liu J; Lacerda AP; Palac H; Shaw T; Mease PJ; Guttman-Yassky E
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36754548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis.
    Katz G; Ogdie A; Baker JF; George MD
    Clin Rheumatol; 2022 May; 41(5):1323-1331. PubMed ID: 35084601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
    Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA.
    Hunter T; Grabner M; Birt J; Isenberg K; Shan M; Teng CC; Wu J; Griffing K; Lisse J; Curtis JR
    Clin Rheumatol; 2022 Sep; 41(9):2863-2874. PubMed ID: 35672618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study.
    Di Martino A; Ursini F; Bordini B; Ancarani C; Ciaffi J; Brunello M; D'Agostino C; Faldini C
    Semin Arthritis Rheum; 2023 Jun; 60():152201. PubMed ID: 37028127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.